Results from Kymriah’s Ph2 ELARA Trial; When Could Kymriah Become Approved in FL? Is Retreatment With Yescarta Commercially Feasible? CBMG Highlights Results From C-CAR066 and C-CAR039; ASCO 2021 Day 3 Part II
Here is a brief preview of this blast: On the third day of ASCO 2021, five key clinical updates were presented from Novartis, Gilead, and CBMG. Below, Celltelligence provides insights and context for each presentation.